FY2022 Q3 Financial and R&D Update

Revenue: Business Units (incl. Forex Impact) (Bn JPY) 0000 Japan Business Daiichi Sankyo Healthcare FY2021 Q3 YTD Results FY2022 Q3 YTD Results YOY 393.7 356.4 -37.3 49.7 54.8 +5.1 Oncolgy Business 49.2 124.7 +75.6 Enhertu 36.6 122.1 +85.5 Turalio 2.0 2.7 +0.6 American Regent 115.6 143.5 +27.9 Injectafer 42.3 41.8 -0.5 Venofer 25.2 38.2 +12.9 GE injectables EU Specialty Business 41.7 51.6 +9.9 97.9 112.5 +14.6 Lixiana 74.3 87.8 +13.5 Nilemdo/Nustendi 2.2 4.9 +2.6 Olmesartan 14.9 14.8 -0.1 ASCA (Asia, South and Central America) Business 82.9 106.4 +23.5 Currency Rate Daiichi-Sankyo USD/JPY 111.10 136.53 +25.43 EUR/JPY 130.62 140.60 +9.98 8

View entire presentation